Japanese Regulators, With Drug Makers Support, Moves Toward East Asian Clinical Data Sharing And Acceptance
This article was originally published in PharmAsia News
Japan is determined to further an initiative in promoting multi-regional clinical study data acceptance among East Asian countries, and the proposal has gained critical support from the nation's drug making industry
You may also be interested in...
Bayer Global Regulatory Affairs Head Joseph Scheeren On MRCT In China: An Interview With PharmAsia News
The possibility China may scale back the acceptance of Multi-Regional Clinical Trial (MRCT) data has become a hot topic between China FDA and industry. On the sidelines of a recent special Asia Pacific Economic Cooperation (APEC) meeting on regional clinical trials, Joseph Scheeren, head of global regulatory affairs for Bayer, shares his views.
Both Japanese and Chinese device makers have reported lower sales and profits linked to a rift over disputed islands, potentially signaling a lengthy period of strained trade ties.
TOKYO - U.S. private equity firm Taiyo Pacific Partners secured a 5 percent stake in CMIC, Japan's largest CRO, highlighting the CRO market growth potential in Japan, despite increased focus on R&D outsourcing to China and India